Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
749
Employees749
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
749
Employees749

NVAX Key Statistics

Market cap
1.63B
Market cap1.63B
Price-Earnings ratio
-6.47
Price-Earnings ratio-6.47
Dividend yield
Dividend yield
Average volume
5.41M
Average volume5.41M
High today
$10.24
High today$10.24
Low today
$9.73
Low today$9.73
Open price
$10.05
Open price$10.05
Volume
4.44M
Volume4.44M
52 Week high
$11.97
52 Week high$11.97
52 Week low
$6.20
52 Week low$6.20

Stock Snapshot

With a market cap of 1.63B, Novavax(NVAX) trades at $9.92. The stock has a price-to-earnings ratio of -6.47.

On 2026-09-10, Novavax(NVAX) stock moved within a range of $9.73 to $10.24. With shares now at $9.92, the stock is trading +2.0% above its intraday low and -3.1% below the session's peak.

Trading activity shows a volume of 4.44M, compared to an average daily volume of 5.41M.

Over the past 52 weeks, Novavax(NVAX) stock has traded between a high of $11.97 and a low of $6.20.

Over the past 52 weeks, Novavax(NVAX) stock has traded between a high of $11.97 and a low of $6.20.

NVAX News

Simply Wall St 4d
Why Novavax Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach

In August 2026, Novavax announced that its partners secured approvals for the updated Nuvaxovid vaccine targeting the SARS-CoV-2 XFG variant for the 2026–2027 s...

Why Novavax Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach
MarketWatch 6d
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
14.3%
Sell
28.6%

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.